Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue

NACompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

March 29, 2022

Primary Completion Date

August 14, 2024

Study Completion Date

August 14, 2024

Conditions
Prostate Cancer
Interventions
DEVICE

Irreversible Electroporation

IRE of the prostate is typically performed with the subject in the lithotomy position, with 2-6 monopolar probes placed through the perineum using a brachytherapy grid and ultrasound or CT guidance. IRE supplies the targeted tissue with high voltage (2-3 kV) direct current pulses lasting up to 100 microseconds through the electrode probes.

Trial Locations (17)

10017

NYU Langone Health, New York

10022

Northwell Health, New York

10065

Memorial Sloan Kettering Cancer Center, New York

Weill Cornell Medicine, New York

19111

Fox Chase Cancer Center, Philadelphia

27710

Duke University, Durham

32610

University of Florida Health, Gainesville

33612

Moffitt Cancer Center, Tampa

45221

University of Cincinnati, Cincinnati

48105

VA Ann Arbor Health Care, Ann Arbor

55905

Mayo Clinic, Rochester

60201

Northshore University Healthsystem, Evanston

60532

Duly Health and Care, Lisle

60612

Rush University Medical Center, Chicago

75390

University of Texas Southwestern Medical Center, Dallas

80045

University of Colorado, Aurora

92868

University of California Irvine, Orange

Sponsors
All Listed Sponsors
lead

Angiodynamics, Inc.

INDUSTRY

NCT04972097 - Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue | Biotech Hunter | Biotech Hunter